Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0752W HIGH $3.95
Volume
47.48 M
Value Traded
595.29 K
Short % Float
20.68%
-37.11%Week
-92.07%1 Month
-93.34%3 Month
-95.23%6 Month
-99.78%5 Year
-99.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.31 M
EPS (TTM)
-2.26
P/E Ratio
-
Ent. Value
198.37 M
Total Shares
30.88 M
Float Shares
29.62 M
Insiders
2.15%
Institutions
20.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BTAI Catalyst Timeline
Dated clinical, regulatory and corporate events for BioXcel Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioXcel Therapeutics, Inc.
563Total events
5Upcoming
128Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆AcquisitionCorporate
Asset sale agreement with Teva Pharmaceuticals as stalking horse bidder
▲Poster PresentationBXCL501FiledPresentation
Poster presentation of new exploratory efficacy data from SERENITY At-Home Phase 3 trial at 2026 ASCP Annual Meeting
agitation associated with bipolar disorders or schizophreniasource ↗
◆Oral PresentationPresentation
Virtual event to discuss commercial launch plan for IGALMI in at-home setting
▲First Patient DosedBXCL501FiledTrial
Enrollment of first patients in DoW-funded Phase 2a trial of BXCL501 for ASR
acute stress reactions (ASR)source ↗
▲FDA Filing AcceptedIGALMIApprovedRegulatory Filing
FDA acceptance of sNDA for IGALMI at-home use
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
▲FDA Filing AcceptedIGALMIApprovedRegulatory Filing
FDA accepted sNDA for IGALMI at-home use
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
▲Topline ReadoutBXCL501FiledClinical Data
Positive Phase 2 topline results from IST for opioid withdrawal
opioid withdrawal symptoms in adults with opioid use disordersource ↗
▼Equity OfferingCorporate
Registered direct offering of 4,500,785 shares and warrants for ~$8.0 million gross proceeds
▲Topline ReadoutBXCL501FiledClinical Data
Positive Phase 2 topline results for BXCL501 in opioid withdrawal
opioid withdrawal symptoms in adults with opioid use disorder (OUD) undergoing a methadone tapersource ↗
●Trial CompletionBXCL501FiledTrial
Trial completed after 80 patients enrolled
opioid withdrawal symptoms in adults with OUD undergoing a methadone tapersource ↗
◆Oral PresentationPresentation
Virtual KOL roundtable on acute agitation in Alzheimer's dementia
Acute agitation in Alzheimer's dementiasource ↗
●Oral PresentationBXCL501FiledPresentation
Virtual KOL roundtable on acute agitation in Alzheimer's dementia
acute agitation associated with Alzheimer's dementiasource ↗
▲Primary Endpoint MetBXCL501FiledClinical Data
Phase 3 SERENITY At-Home safety trial met primary endpoint
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
▲FDA Feedback ReceivedIGALMIApprovedFDA Meeting
Positive FDA feedback following pre-sNDA meeting
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
●sNDA SubmissionIGALMIApprovedRegulatory Filing
sNDA submitted to FDA for IGALMI label expansion in at-home setting
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
●sNDA SubmissionIGALMIApprovedRegulatory Filing
sNDA submitted for IGALMI label expansion to at-home setting
acute agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
▲Product LaunchIGALMIApprovedPost-Market
Potential launch of IGALMI in at-home setting
acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingsource ↗
▲FDA Filing AcceptedIGALMIApprovedRegulatory Filing
sNDA for IGALMI at-home use accepted by FDA
acute treatment of agitation associated with bipolar disorders or schizophrenia in at-home settingsource ↗
◆Timing GuidanceBXCL501FiledPresentation
Planned sNDA submission for label expansion of IGALMI to at-home setting
agitation associated with bipolar disorders or schizophreniasource ↗
●Oral PresentationIGALMIApprovedPresentation
Virtual roundtable on self-administered treatments at home
acute agitation associated with neuropsychiatric conditionssource ↗
▲Trial CompletionBXCL501FiledTrial
SERENITY At-home Phase 3 trial completed
Agitation Associated With Bipolar Disorder or Schizophreniasource ↗
▲Full ResultsBXCL501FiledClinical Data
Full results of SERENITY At-home presented
Agitation Associated With Bipolar Disorder or Schizophreniasource ↗
▲Full ResultsBXCL501FiledClinical Data
Positive results from correlation study supporting SERENITY At-Home exploratory efficacy outcomes
acute agitation associated with schizophrenia and bipolar disordersource ↗
▲Trial CompletionIGALMIApprovedTrial
Successful completion of SERENITY At-Home pivotal trial for IGALMI
agitation associated with bipolar disorders and schizophreniasource ↗
▲Topline ReadoutBXCL501FiledClinical Data
Positive topline exploratory efficacy data from SERENITY At-Home trial
agitation associated with bipolar disorders or schizophreniasource ↗
●Oral PresentationBXCL501FiledPresentation
Virtual KOL call with Dr. Leslie Citrome on SERENITY At-Home program
agitation associated with bipolar disorders or schizophreniasource ↗
◆Oral PresentationPresentation
BioXcel Therapeutics to present at H.C. Wainwright 27th Annual Global Investment Conference
◆Topline ReadoutBXCL501FiledClinical Data
Topline results from SERENITY At-Home pivotal Phase 3 safety trial
agitation associated with bipolar disorders or schizophreniasource ↗
▲Primary Endpoint MetBXCL501FiledClinical Data
SERENITY At-Home pivotal Phase 3 trial met primary endpoint of being well tolerated in at-home treatment
agitation associated with bipolar disorders or schizophreniasource ↗
◆Oral PresentationBXCL501FiledPresentation
Conference call to discuss SERENITY At-Home trial results
agitation associated with bipolar disorders or schizophreniasource ↗
▲Pre NDA MeetingBXCL501FiledFDA Meeting
Pre-sNDA meeting originally scheduled for August 20, 2025, no longer required
Agitation associated with bipolar disorders or schizophreniasource ↗
◆Pre NDA MeetingIGALMIApprovedFDA Meeting
Pre-sNDA meeting with FDA scheduled for August 20, 2025
agitation associated with bipolar disorders or schizophreniasource ↗
▲Enrollment CompleteBXCL501FiledTrial
Database lock completed for SERENITY At-Home pivotal Phase 3 safety trial
acute treatment of agitation associated with bipolar disorders or schizophreniasource ↗
◆Oral PresentationPresentation
CEO Vimal Mehta to participate in virtual fireside chat at H.C. Wainwright HCW@Home series
▲FDA Feedback ReceivedBXCL501FiledFDA Meeting
Positive pre-sNDA meeting comments received from FDA
Agitation associated with bipolar disorders or schizophreniasource ↗
◆Oral PresentationPresentation
BioXcel Therapeutics to participate in fireside chat at Canaccord Genuity 45th Annual Growth Conference
▲PublicationBXCL501FiledPresentation
Publication in Frontiers in Pharmacology on dexmedetomidine effects on stress-mediated behaviors
stress-related disorderssource ↗
◆Topline ReadoutBXCL501FiledClinical Data
Topline data readout from SERENITY At-Home trial expected in August
acute treatment of agitation associated with bipolar disorders or schizophreniasource ↗
▲Last Patient Last VisitBXCL501FiledTrial
Last patient last visit in SERENITY At-Home Phase 3 trial
agitation associated with bipolar disorders or schizophreniasource ↗
◆Timing GuidanceIGALMIApprovedPresentation
FDA meeting scheduled in August to support potential sNDA submission for label expansion of IGALMI
acute treatment of agitation associated with bipolar disorders or schizophreniasource ↗
Past FDA Catalysts and PDUFA Decisions
How BTAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | BXCL501 (IGALMI) | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$4M
Pipeline Value
$1M
Commercial Value
Undervalued
Valuation Signal
3
Drugs Scored
2.8x
rNPV / MCap
BioXcel Therapeutics, Inc. faces pipeline headwinds (36/100), with $585M risk-adjusted pipeline value, led by BXCL701 in Prostate Cancer (Phase 1), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $0.7M x 1.0 = $1M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| IGALMI | $1M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BXCL701 Small moleculeNCT05558982 | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | ACTIVE NOT_RECRUITING | 22 | Sep 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every BTAI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BXCL501 BreakthroughFast Track | agitation associated with bipolar disorders or schizophrenia | Phase 3 | 2026-05-28 | BXCL501 significantly reduced agitation across various severity levels, with the most notable effects in severe cases.Read More | BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rodriguez JavierOfficer (See Remarks) | Option | 35 26,838 held | $0.00 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BTAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 10.00 K | 439.50 K |
BTAI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BTAI ranks across every disease it competes in
Competitive Position is a premium feature
See how BTAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBTAI News
About BioXcel Therapeutics, Inc.
Headquarters555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
BIOPHARMAWATCH ELITE PLUS
Trade the next BTAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime